Sitryx

Sitryx Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics that modulate immune cell metabolism to achieve disease remission in autoimmune and inflammatory conditions.

The company's approach targets novel metabolic enzymes within immune cells, with lead programmes in atopic dermatitis and psoriatic arthritis.

Founded by researchers in immunology and metabolism, Sitryx has attracted investment from major pharmaceutical companies and specialist life science funds.